Sapphire 3 CTO Study
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.
Also called NCT06358508
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 170 participants
- Sponsor
- Registry
-
NCT06358508
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Spain
- Registry status
- Completed
Technical summary
Registry record NCT06358508. Allocation not applicable; no masking; primary purpose treatment. Start 2024-11-06 (actual); primary completion 2025-10-21 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Sapphire 3 CTO Study
- Condition
- Coronary Artery Disease
- Condition
- Coronary Disease
- Condition
- Myocardial Ischemia
- Condition
- Heart Diseases
- Condition
- Arteriosclerosis
- Condition
- Cardiovascular Diseases
- Condition
- Chronic Total Occlusion
- Condition
- Chronic Total Occlusion of Coronary Artery
- Intervention (Device)
- Sapphire 3 Coronary Dilatation Catheter
- Lead sponsor
- OrbusNeich
- Collaborator
- Avania
Record details
- Record id
cardio:ct-nct06358508- Content hash
5da901c809f494e156547c56c267cd43aa4dbdeb0be8e3701a7648c0a98f2315